Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

被引：0
|
作者：
Tim Heise
Leo Seman
Sreeraj Macha
Peter Jones
Alexandra Marquart
Sabine Pinnetti
Hans J. Woerle
Klaus Dugi
机构：
[1] Profil Institut für Stoffwechselforschung GmbH,
[2] Boehringer Ingelheim Pharmaceuticals,undefined
[3] Inc.,undefined
[4] With Confidence Ltd.,undefined
[5] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[6] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[7] Boehringer Ingelheim GmbH,undefined
来源：
Diabetes Therapy | 2013年 / 4卷
关键词：
BI 10773; Diabetes; Empagliflozin; Pharmacodynamics; Pharmacokinetics; Safety; Tolerability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：331 / 345
页数：14
相关论文
共 50 条
  • [1] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Heise, Tim
    Seman, Leo
    Macha, Sreeraj
    Jones, Peter
    Marquart, Alexandra
    Pinnetti, Sabine
    Woerle, Hans J.
    Dugi, Klaus
    DIABETES THERAPY, 2013, 4 (02) : 331 - 345
  • [2] Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus
    Kanada, Shigeto
    Koiwai, Kazuki
    Taniguchi, Atsushi
    Sarashina, Akiko
    Seman, Leo
    Woerle, Hans J.
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (06) : 613 - 617
  • [3] Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus
    Kothare, Prajakti A.
    Linnebjerg, Helle
    Isaka, Yoshitaka
    Uenaka, Kazunori
    Yamamura, Ayuko
    Yeo, Kwee Poo
    de la Pena, Amparo
    Teng, Choo Hua
    Mace, Kenneth
    Fineman, Mark
    Shigeta, Hirofumi
    Sakata, Yukikuni
    Irie, Shin
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (12): : 1389 - 1399
  • [4] Multiple dose safety, tolerability, and Pharmacokinetics/Pharmacodynamics of exenatide in Japanese patients with type 2 diabetes
    Kothare, Prajakti
    Linnebjerg, Helle
    Isaka, Yoshitaka
    Uenaka, Kazunori
    Yamamura, Ayuko
    Shigeta, Hirofumi
    Yeo, Kwee Poo
    Teng, Choo Hua
    De La Apena, Amparo
    Mace, Kenneth
    Fineman, Mark
    Sakata, Yukikuni
    Irie, Shin
    DIABETES, 2006, 55 : A461 - A461
  • [5] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Kinduryte Schorling, Ona
    Clark, Douglas
    Zwiener, Isabella
    Kaspers, Stefan
    Lee, Jisoo
    Iliev, Hristo
    ADVANCES IN THERAPY, 2020, 37 (08) : 3463 - 3484
  • [6] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Ona Kinduryte Schorling
    Douglas Clark
    Isabella Zwiener
    Stefan Kaspers
    Jisoo Lee
    Hristo Iliev
    Advances in Therapy, 2020, 37 : 3463 - 3484
  • [7] Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
    Heise, T.
    Seewaldt-Becker, E.
    Macha, S.
    Hantel, S.
    Pinnetti, S.
    Seman, L.
    Woerle, H. J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07): : 613 - 621
  • [8] Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    Kolterman, OG
    Kim, DD
    Shen, L
    Ruggles, JA
    Nielsen, LL
    Fineman, MS
    Baron, AD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (02) : 173 - 181
  • [9] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kaspers, Stefan
    Woerle, Hans J.
    Kim, Gabriel
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1299 - 1313
  • [10] Safety and tolerability of empagliflozin in patients with Type 2 diabetes
    Salsali, A.
    Kohler, S.
    Hantel, S.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2016, 33 : 66 - 66
12345